Abstract
Wear particle-induced aseptic loosening has been recognized as a harmful inflammatory process that jeopardizes the longevity of total joint replacement. The proteasome controls the activation of NF-κB and subsequent inflammatory mediators, such as TNF-α and IL-1β; thus, we investigated whether proteasome inhibition can ameliorate wear particle-induced inflammation in a murine model. A total of 48 BALB/C mice were divided into four groups. Titanium (Ti) particles were injected into the established air pouches of all mice (except negative controls) to provoke inflammation, and then 0.1 or 0.5 mg/kg of Bortezomib (Bzb, a proteasome inhibitor) was administered to ameliorate the inflammation response, while air pouches without Bzb administration were used as loading controls. The air pouches were harvested 2 or 7 days after Bzb injection for molecular and histological analyses. Inflammation responses in the air pouch tissues of Bzb treatment groups are lower than those in the Ti-stimulated group, and this occurs in a dose-dependent manner. Bzb can significantly attenuate the severity of Ti-induced inflammation in air pouches.
Similar content being viewed by others
References
Daniel, J., P. Pynsent, and D. McMinn. 2004. Metal-on-metal resurfacing of the hip in patients under the age of 55 years with osteoarthritis. Journal of Bone and Joint Surgery. British Volume 86(2): 177–184.
Sundfeldt, M., L.V. Carlsson, C.B. Johansson, P. Thomsen, and C. Gretzer. 2006. Aseptic loosening, not only a question of wear: A review of different theories. Acta Orthopaedica 77(2): 177–197.
Mabilleau, G., Y.M. Kwon, H. Pandit, D.W. Murray, and A. Sabokbar. 2008. Metal-on-metal hip resurfacing arthroplasty: A review of periprosthetic biological reactions. Acta Orthopaedica 79(6): 734–747.
Purdue, P.E., P. Koulouvaris, B.J. Nestor, and T.P. Sculco. 2006. The central role of wear debris in periprosthetic osteolysis. HSS Journal 2(2): 102–113.
Ingham, E., and J. Fisher. 2005. The role of macrophages in osteolysis of total joint replacement. Biomaterials 26(11): 1271–1286.
Ren, W., X.H. Li, B.D. Chen, and P.H. Wooley. 2004. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF-κB activity. Journal of Orthopaedic Research 22(1): 21–29.
Goodman, S.B., M. Trindade, T. Ma, M. Genovese, and R.L. Smith. 2005. Pharmacologic modulation of periprosthetic osteolysis. Clinical Orthopaedics and Related Research 430: 39–45.
Paramore, A., and S. Frantz. 2003. Bortezomib. Nature Reviews. Drug Discovery 2(8): 611–612.
Diptendu, S., L. Khanh, K. Tapas, J. Bryan, P. Thomas, B. Lionel, and P. Edward. 2006. Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-γ mechanistic insights and implications for periprosthetic osteolysis. Journal of Bone and Joint Surgery. American Volume 88(4): 788–799.
Wooley, P.H., R. Morren, J. Andary, S. Sud, S.Y. Yang, L. Mayton, D. Markel, A. Sieving, and S. Nasser. 2002. Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials 23(2): 517–526.
Ren, W., D. Markel, R. Schwendener, Y. Ding, B. Wu, and P. Wooley. 2008. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model. Journal of Biomedical Materials Research. Part A 85(4): 1043–1051.
Edwards, J., A. Sedgwick, and D. Willoughby. 1981. The formation of a structure with the features of synovial lining by subcutaneous injection of air: An in vivo tissue culture system. The Journal of Pathology 134(2): 147–156.
Ciechanover, A. 1994. The ubiquitin–proteasome proteolytic pathway. Cell 79(1): 13–21.
Goldberg, A.L. 2003. Protein degradation and protection against misfolded or damaged proteins. Nature 426(6968): 895–899.
Richardson, P.G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S.V. Rajkumar, G. Srkalovic, M. Alsina, and R. Alexanian. 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine 348(26): 2609–2617.
Lee, S.W., J.H. Kim, Y.B. Park, and S.K. Lee. 2009. Bortezomib attenuates murine collagen-induced arthritis. Annals of the Rheumatic Diseases 68(11): 1761–1767.
Yannaki, E., A. Papadopoulou, E. Athanasiou, P. Kaloyannidis, A. Paraskeva, D. Bougiouklis, P. Palladas, M. Yiangou, and A. Anagnostopoulos. 2010. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis and Rheumatism 62(11): 3277–3288.
Lawrence, T. 2009. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harbor Perspectives in Biology 1(6): a001651.
Mankan, A.K., M.W. Lawless, S.G. Gray, D. Kelleher, and R. McManus. 2009. NF-κB regulation: The nuclear response. Journal of Cellular and Molecular Medicine 13(4): 631–643.
Karin, M., Y. Yamamoto, and Q.M. Wang. 2004. The IKK NF-κB system: A treasure trove for drug development. Nature Reviews. Drug Discovery 3(1): 17–26.
Jimi, E., K. Aoki, H. Saito, F. D’Acquisto, M.J. May, I. Nakamura, T. Sudo, T. Kojima, F. Okamoto, and H. Fukushima. 2004. Selective inhibition of NF-kappaB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nature Medicine 10(6): 617–624.
Xu, J., H.F. Wu, E.S.M. Ang, K. Yip, M. Woloszyn, M.H. Zheng, and R.X. Tan. 2009. NF-κB modulators in osteolytic bone diseases. Cytokine & Growth Factor Reviews 20(1): 7–17.
Jones, L.C., C. Frondoza, and D.S. Hungerford. 1999. Immunohistochemical evaluation of interface membranes from failed cemented and uncemented acetabular components. Journal of Biomedical Materials Research 48(6): 889–898.
Stea, S., M. Visentin, D. Granchi, G. Ciapetti, M. Donati, A. Sudanese, C. Zanotti, and A. Toni. 2000. Cytokines and osteolysis around total hip prostheses. Cytokine 12(10): 1575–1579.
Epstein, F.H., P.J. Barnes, and M. Karin. 1997. Nuclear factor-кB-a pivotal transcription factor in chronic inflammatory disease. The New England Journal of Medicine 336(15): 1066–1071.
Baumann, H., and J. Gauldie. 1994. The acute phase response. Immunology Today 15(2): 74–80.
Lin, E., S.E. Calvano, and S.F. Lowry. 2000. Inflammatory cytokines and cell response in surgery. Surgery 127(2): 117–126.
Cheng, T., G.Y. Zhang, C.J. Guo, and X. Zhang. 2010. Effects of NF-κB inhibitor on titanium particulate-induced inflammation in a murine model. Journal of Surgical Research 162(2): 225–230.
Zhou, F., X. Zhu, H. Mao, H. Yang, D. Geng, and Y. Xu. 2010. Effects of a cannabinoid receptor 2 selective antagonist on the inflammatory reaction to titanium particles in vivo and in vitro. The Journal of International Medical Research 38(6): 2023–2032.
Hofbauer, L., D. Lacey, C. Dunstan, T. Spelsberg, B. Riggs, and S. Khosla. 1999. Interleukin-1 [beta] and tumor necrosis factor-[alpha], but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25(3): 255–259.
Acknowledgments
This work was supported by the Integration of Medicine and Engineering Foundation of Shanghai Jiaotong University (YG2010MS33).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mao, X., Pan, X., Cheng, T. et al. Therapeutic Potential of the Proteasome Inhibitor Bortezomib on Titanium Particle-Induced Inflammation in a Murine Model. Inflammation 35, 905–912 (2012). https://doi.org/10.1007/s10753-011-9392-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-011-9392-7